645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

Authors :: Joaquin Mateo
J. Chakrabarti
H-C. Chen
N.D. Shore
Arun Azad
A. Niyazov
Fred Saad
Neeraj Agarwal
Silvana Lanzalone
Source :: Annals of Oncology. 32:S672-S673
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
Placebo
Castration-sensitive prostate cancer
law.invention
Double blind
chemistry.chemical_compound
chemistry
Randomized controlled trial
law
Internal medicine
medicine
Talazoparib
Enzalutamide
In patient
business
Gene

Full Text Access

Tools